Jan 28, 2020· Comment from Association for Accessible Medicines (AAM) and its Biosimilars Council· FDA-2019-D-5255-0014
Please see attached for full comments from the Association for Accessible Medicines (AAM) and its Biosimilars Council.
FDANonrulemakingFDA-2019-D-5255
Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products; Draft Guidance for Industry; Availability
RIN
—
Last modified
Jan 30, 2020
Comment window
closed 2373d ago
Association for Accessible Medicines filings
1
Activity
Association for Accessible Medicines filed 1 comment on this docket between Jan 28, 2020 and Jan 28, 2020. 5 other organizations filed here. The comment window closed 2373d ago.
What Association for Accessible Medicines filed (1)
Abstract
No abstract recorded.
View on regulations.gov →Co-filers (5)
See everyone who commented →- Association for Accessible MedicinesTHIS ORG1 filing · confidence 97%
- American Diabetes Associationtrade assoc.1 filing · confidence 85%
- American Pharmacists Association (APhA)trade assoc.1 filing · confidence 97%
- Association for Accessible Medicines (AAM) and its Biosimilars Counciltrade assoc.1 filing · confidence 85%
- Eli Lilly and Companyunverified attribution1 filing · confidence 70%
- Vizient Inc.unverified attribution1 filing · confidence 70%